Vyome Therapeutics is a technology company.
Vyome Therapeutics has raised $78.0M across 4 funding rounds.
Vyome Therapeutics has raised $78.0M in total across 4 funding rounds.
Vyome Therapeutics has raised $78.0M in total across 4 funding rounds.
Vyome Therapeutics's investors include Accel, B Capital Group, DFJ, Greylock, Oren Yunger, Obvious Ventures, REMUS Capital, S28 Capital, Sapphire Ventures, Signal Peak Ventures, Silicon Valley Connect, Team8.
Vyome Therapeutics (now Vyome Holdings, Inc., Nasdaq: HIND) is a Cambridge, MA-based clinical-stage biotech company developing locally-acting therapies for immuno-inflammatory diseases and rare conditions with unmet needs.[2][3][4] It builds a global healthcare platform synergizing biotech, medical devices, and AI across the US-India innovation corridor, serving patients with conditions like malignant fungating wounds, acne vulgaris, and uveitis by repositioning proven drugs into targeted treatments that reduce side effects and costs.[1][2][4] The company solves high-risk development challenges through capital-efficient strategies, leveraging Indian networks for patient access, data, and regulatory expertise, with strong growth momentum from Phase II trial completions, upcoming pivotal trials, and $47.3M in total funding including a recent $22M round.[1][3]
Vyome went public via reverse merger with Reshape Life Sciences, emphasizing its US registration while tapping Indian biotech strengths for pipeline advancement in underserved areas.[1][2]
Vyome Therapeutics was founded by Shiladitya Sengupta, who brings expertise in biotech and healthcare, with the company operating for nearly a decade from Princeton, New Jersey roots before establishing its principal office in Harvard Square, Cambridge, MA.[1][2][3] The idea emerged from recognizing unmet needs in immuno-inflammatory diseases, investing millions to build a portfolio of assets with strong mechanistic science, including site-targeted drugs like VB-1953 for acne and programs for malignant fungating wounds.[3][4]
Early traction came from positive Phase II data for VB-1953 in moderate-to-severe inflammatory facial acne, demonstrating statistically significant efficacy, alongside preclinical advances in uveitis eye-drop formulations.[1][3] A pivotal moment was the strategic reverse merger to go public, enabling US investor access while scaling via the US-India corridor with co-founders' government and industry networks.[1]
Vyome rides the US-India biotech corridor boom, capitalizing on India's vast patient pools, med tech/AI talent, and cost advantages amid global demand for affordable, innovative therapies in stagnant immuno-inflammatory markets.[1][2][4] Timing aligns with rising focus on drug repurposing to de-risk pipelines post-pandemic, plus AI-driven healthcare transformation where Vyome's platform integrates data intelligence for better outcomes.[1][4]
Market forces favoring Vyome include unmet needs in rare diseases (e.g., fungating wounds), regulatory tailwinds for topical/local therapies, and investor appetite for efficient biotechs bridging emerging markets to US standards.[1][3] It influences the ecosystem by pioneering cross-border models, potentially unlocking AI-centric tools and devices to scale impact beyond pharma.[2][4]
Over the next 12-18 months, Vyome eyes pivotal trials for malignant fungating wounds, Asian acne expansion, new INDs, and med tech/AI partnerships to build a high-value platform.[1] Trends like AI in drug discovery, India’s biotech surge, and demand for side-effect-minimal therapies will propel growth, evolving its influence from niche pipeline player to diversified healthcare innovator.[2][4] With clinical catalysts and Nasdaq visibility, Vyome is positioned for outsized returns in underserved immuno-inflammatory spaces, transforming patient lives through efficient, corridor-spanning innovation.[1][2]
Vyome Therapeutics has raised $78.0M across 4 funding rounds. Most recently, it raised $22.0M Series D in December 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2018 | $22.0M Series D | Accel, B Capital Group, DFJ, Greylock, Oren Yunger, Obvious Ventures, REMUS Capital, S28 Capital, Sapphire Ventures, Signal Peak Ventures, Silicon Valley Connect, Team8, Tekton Ventures, TY, WndrCo LLC, Alice Lloyd George, Arash Ferdowsi, Drew Houston, George Hu | |
| Aug 1, 2016 | $14.0M Series C | 3one4 Capital, Accel, B Capital Group, Greylock, Oren Yunger, Obvious Ventures, REMUS Capital, S28 Capital, Sapphire Ventures, Signal Peak Ventures, Silicon Valley Connect, Team8, Tekton Ventures, TY, WndrCo LLC, Alice Lloyd George, Arash Ferdowsi, Drew Houston, George Hu | |
| Aug 1, 2014 | $8.0M Series B | 3one4 Capital | |
| Sep 1, 2012 | $34.0M Series A | 3one4 Capital |